Capability of SART3109-118 peptide to induce cytotoxic T lymphocytes from prostate cancer patients with HLA class I-A11, -A31 and -A33 alleles

  • Authors:
    • Elnisr Rashed Mohamed
    • Masayasu Naito
    • Yasunobu Terasaki
    • Yamei Niu
    • Shojiro Gohara
    • Nobukazu Komatsu
    • Shigeki Shichijo
    • Kyogo Itoh
    • Masanori Noguchi
  • View Affiliations

  • Published online on: February 1, 2009     https://doi.org/10.3892/ijo_00000178
  • Pages: 529-536
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

We previously reported the SART3 gene to be a tumor-rejection antigen gene encoding a peptide at positions 109-118 (SART3109-118) with the ability to induce HLA-A24-restricted cytotoxic T lymphocytes. In this study, we investigated both humoral and cellular responses to this peptide in cancer patients with alleles other than HLA-A24 to explore the possibility of using this peptide as a cancer vaccine for these patients. IgG reactive to SART3109-118 peptide was identified in sera of the vast majority of non-cancer subjects (n=50) and all cancer patients (n=50) tested without apparent HLA-A association. Levels of anti-SART3109-118 peptide antibody in cancer patients were significantly higher than those of non-cancer subjects, but no difference was found between HLA-A24+A2− and HLA-A24−A2+ cancer patients. This peptide induced cancer cell-reactive cytotoxic T lymphocytes from peripheral blood mononuclear cells of both healthy donors and prostate cancer patients with HLA-A11, HLA-A31 and HLA-A33 alleles, but not with HLA-A2. These results suggest that this peptide can be applicable as a cancer vaccine not only for HLA-A24+, but also for HLA-A11+, HLA-A31+ and HLA-A33+ prostate cancer patients.

Related Articles

Journal Cover

February 2009
Volume 34 Issue 2

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Mohamed, E.R., Naito, M., Terasaki, Y., Niu, Y., Gohara, S., Komatsu, N. ... Noguchi, M. (2009). Capability of SART3109-118 peptide to induce cytotoxic T lymphocytes from prostate cancer patients with HLA class I-A11, -A31 and -A33 alleles. International Journal of Oncology, 34, 529-536. https://doi.org/10.3892/ijo_00000178
MLA
Mohamed, E. R., Naito, M., Terasaki, Y., Niu, Y., Gohara, S., Komatsu, N., Shichijo, S., Itoh, K., Noguchi, M."Capability of SART3109-118 peptide to induce cytotoxic T lymphocytes from prostate cancer patients with HLA class I-A11, -A31 and -A33 alleles". International Journal of Oncology 34.2 (2009): 529-536.
Chicago
Mohamed, E. R., Naito, M., Terasaki, Y., Niu, Y., Gohara, S., Komatsu, N., Shichijo, S., Itoh, K., Noguchi, M."Capability of SART3109-118 peptide to induce cytotoxic T lymphocytes from prostate cancer patients with HLA class I-A11, -A31 and -A33 alleles". International Journal of Oncology 34, no. 2 (2009): 529-536. https://doi.org/10.3892/ijo_00000178